RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer ImmunotherapyAlmost all solid tumors displaying hypoxic areas in the tumor microenvironment (TME) are associated with therapeutic failure. It is now well established that the abnormal growth of malignant solid tumors exacerbates their susceptibility to hypoxia. Cold tumors are typically hypoxic which manifest an immunosuppressive (hostile) TME.
Therefore, having the ability to target hypoxia, convert an otherwise immunosuppressive TME and sensitize tumors to various therapies such as immune checkpoint inhibitors is an attractive strategy that ONCY’s pelareorep has been demonstrating in both the AWARE-1 and Bracelet-1 studies. The results of these clinical studies is supported by previously cited research that demonstrated that the systemic administration of ONCY’s pelareorep down-regulates HIF-1 and its target genes which are known to be involved in the establishment of hypoxic stress in the tumor microenvironment (TME).